Compare PANL & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PANL | ZVRA |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 485.4M | 562.2M |
| IPO Year | 2015 | 2015 |
| Metric | PANL | ZVRA |
|---|---|---|
| Price | $7.39 | $11.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $9.00 | ★ $23.00 |
| AVG Volume (30 Days) | 299.6K | ★ 1.4M |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 159.21 |
| EPS | 0.21 | ★ 0.74 |
| Revenue | ★ $385,088,209.00 | $106,470,000.00 |
| Revenue This Year | $0.72 | $37.27 |
| Revenue Next Year | N/A | $53.42 |
| P/E Ratio | $35.33 | ★ $15.62 |
| Revenue Growth | N/A | ★ 350.91 |
| 52 Week Low | $4.56 | $7.16 |
| 52 Week High | $9.39 | $15.04 |
| Indicator | PANL | ZVRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.58 | 48.30 |
| Support Level | $7.11 | $8.26 |
| Resistance Level | $7.85 | $12.06 |
| Average True Range (ATR) | 0.24 | 0.57 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 30.09 | 62.43 |
Pangaea Logistics Solutions Ltd and its subsidiaries collectively, Pangaea or the Company, provide seaborne drybulk logistics and transportation services as well as terminal and stevedoring services. Pangaea utilizes its logistics expertise to service a broad base of industrial customers who require the transportation of a wide variety of dry bulk cargoes, including grains, coal, iron ore, pig iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The Company's operating segments include the shipping segment: The Company's operating segments include the shipping segment and six terminal and stevedoring operating segments. The company operates in the USA, Germany, Canada, Singapore, the United Kingdom, and other countries, with maximum from the USA and others.
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.